horizon

ONCOBIOME: Gut OncoMicrobiome Signatures associated with cancer incidence, prognosis and prediction of treatment response
Exploiting the gut microbiome for cancer diagnosis and treatment
ONCOBIOME: Gut OncoMicrobiome Signatures associated with cancer incidence, prognosis and prediction of treatment response
A Phase Ia/b study of MEK1/2 inhibitor PD-0325901 or MEK-162 with cMET inhibitor PF-02341066 in RASMT and RASWT (with aberrant c-MET) Colorectal Cancer Patients.
Clinical trial for cMET inhibitor
A Phase Ia/b study of MEK1/2 inhibitor PD-0325901 or MEK-162 with cMET inhibitor PF-02341066 in RASMT and RASWT (with aberrant c-MET) Colorectal Cancer Patients.